Refile: Kura Oncology records revenue in Q1, but loss widens on higher costs

Kura Oncology

12/05/2026 21:09

Corrects typo in headline

Overview

US cancer drug maker's Q1 net product revenue reached $5.8 mln in first full commercial quarter

Company reported robust new patient starts and early launch momentum for KOMZIFTI

Collaboration revenue declined yr/yr, net loss widened due to higher R&D and SG&A expenses

Outlook

Company expects multiple clinical data readouts for ziftomenib in 2026 across AML settings

Kura expects current cash and collaboration payments to fund ziftomenib program through 2028 topline results

Company aims for sustained quarter-over-quarter growth in KOMZIFTI revenue and adoption

Result Drivers

EARLY LAUNCH MOMENTUM - Co cited robust new patient starts, repeat use, switching from other therapies, and initial combination adoption as drivers of KOMZIFTI revenue

PAYER ACCESS - Broad and rapid payer access with over 93% coverage supported commercial uptake

COMMERCIAL INVESTMENT - Higher R&D and SG&A expenses driven by advancement of ziftomenib combination trials and commercialization investments

Company press release: ID:nGNXbPd0tf

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.83
Q1 Net Income
-$73.33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Kura Oncology Inc is $28.00, about 194.4% above its May 11 closing price of $9.51

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)